T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.18% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Carter's
CRI
$1.42B
| $2.02M | ﹤0.01% |
28,619
-45
| -0.2% | -$3.62K |
|
1602
Saic
SAIC
$5.36B
| $2.01M | ﹤0.01% |
21,636
+1,518
| +8% | +$133K |
|
1603
Thor Industries
THO
$4.11B
| $2M | ﹤0.01% |
26,714
+84
| +0.3% | +$6.51K |
|
1604
KB Home
KBH
$3.44B
| $1.99M | ﹤0.01% |
70,036
+1,334
| +2% | +$42.6K |
|
1605
New York Times
NYT
$10.4B
| $1.99M | ﹤0.01% |
71,230
+4,172
| +6% | +$151K |
|
1606
Liberty Media Series A
FWONA
$23.9B
| $1.99M | ﹤0.01% |
35,769
-2,648
| -7% | -$147K |
|
|
MEKA
1607
DELISTED
MELI Kaszek Pioneer Corp Class A Ordinary Shares
MEKA
| $1.96M | ﹤0.01% |
197,938
| – | – |
|
1608
Leggett & Platt
LEG
$1.32B
| $1.96M | ﹤0.01% |
56,604
+312
| +0.6% | +$11.4K |
|
1609
Olin
OLN
$2.18B
| $1.96M | ﹤0.01% |
42,285
+216
| +0.5% | +$12.5K |
|
1610
Innospec
IOSP
$2.31B
| $1.95M | ﹤0.01% |
20,364
+200
| +1% | +$19.4K |
|
1611
Seres Therapeutics
MCRB
$45.6M
| $1.95M | ﹤0.01% |
28,435
+25
| +0.1% | +$2.15K |
|
|
SF
1612
Stifel
SF
$12.9B
| $1.95M | ﹤0.01% |
52,200
+310
| +0.6% | +$12.9K |
|
1613
Cousins Properties
CUZ
$4.89B
| $1.95M | ﹤0.01% |
66,652
+229
| +0.3% | +$7.92K |
|
1614
Ameris Bancorp
ABCB
$6.02B
| $1.94M | ﹤0.01% |
48,375
+341
| +0.7% | +$14.5K |
|
1615
Matthews International
MATW
$725M
| $1.94M | ﹤0.01% |
67,697
+233
| +0.3% | +$7.12K |
|
|
ALLK
1616
DELISTED
Allakos
ALLK
| $1.94M | ﹤0.01% |
618,191
-55,545
| -8% | -$208K |
|
1617
AGNC Investment
AGNC
$13B
| $1.93M | ﹤0.01% |
174,673
-6,268
| -3% | -$74.3K |
|
|
CIVI
1618
DELISTED
Civitas Resources
CIVI
| $1.93M | ﹤0.01% |
36,992
+3,004
| +9% | +$196K |
|
1619
Remitly
RELY
$5.54B
| $1.93M | ﹤0.01% |
252,340
+148,966
| +144% | +$1.48M |
|
|
DCPH
1620
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.93M | ﹤0.01% |
+146,799
| New | +$1.62M |
|
|
PACW
1621
DELISTED
PacWest Bancorp
PACW
| $1.92M | ﹤0.01% |
72,069
+9,027
| +14% | +$292K |
|
|
NEWR
1622
DELISTED
New Relic, Inc.
NEWR
| $1.91M | ﹤0.01% |
38,108
-1,665
| -4% | -$92.4K |
|
|
VG
1623
DELISTED
Vonage Holdings Corporation
VG
| $1.91M | ﹤0.01% |
101,222
+6,948
| +7% | +$133K |
|
1624
Hope Bancorp
HOPE
$1.85B
| $1.91M | ﹤0.01% |
137,695
+830
| +0.6% | +$12.1K |
|
1625
O-I Glass
OI
$1.04B
| $1.9M | ﹤0.01% |
135,872
-14,923
| -10% | -$215K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.